Company Unveils Industry’s First GenAI Solution for Healthcare Providers and Patients to Increase Access to Care
Leal Health, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, released the first-of-its-kind GenAI single point of access technology, allowing healthcare providers (HCPs), caregivers and cancer patients to understand diagnostics and identify personalized treatment options to support the treatment decision process. Leal’s technology also includes financial aid, schedule management and other patient support resources, removing barriers to care.
“As the rate of late-stage cancer diagnoses continues to accelerate, patients need more support than ever before. They want to better understand their condition and are searching for treatment options, trying to gain access to treatments and navigating the extensive financial implications of their diagnosis,” said Tzvia Bader, Co-Founder and CEO, Leal Health. “Leal’s next-generation platform empowers patients and often constrained clinical support teams with a single point of access that accurately and instantaneously addresses these challenges during any point of a patient’s treatment journey.”
Leal’s AI-based patient engagement platform leverages its proprietary Large Language Model (LLM) with patented Precise Medical Modeling and machine learning capabilities to:
- Read and analyze medical documents, such as next-generation sequencing (NGS) and biopsy reports
- Provide precision treatment options (clinical trials and FDA-approved therapies) based on patients’ unique medical conditions
- Offer a live GenAI-enabled chat resource to further support, engage and educate patients
- Identify financial support options to assist with copays, transportation, childcare and more
- Help manage testing schedules to ensure patients are always aware of their upcoming tests
Ms. Bader added, “With our proprietary, longitudinal, real-world data gathered throughout patient journeys, our goal is to simplify the process and eliminate barriers that currently hinder access to lifesaving cancer care. By doing this, we are also accelerating biopharmaceutical companies in their commitment to patient-centric approaches throughout the patient journey.”
Source: PRNewsWire
